BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease

**Title: 18-Month Data from Phase 1 Trial of Parkinson’s Cell Therapy Published in Nature**

BlueRock Therapeutics LP has released findings from its Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease. The data, spanning 18 months, was published in the scientific journal *Nature*. BlueRock Therapeutics is a clinical-stage company and a subsidiary of Bayer AG.

The trial, known as exPDite, explores the potential of bemdaneprocel to address neurological damage caused by Parkinson’s disease. Claire Henchcliffe, MD, chair of the Department of Neurology at UC Irvine School of Medicine and one of the study’s principal investigators, described the approach as aiming to “rebuild brain networks lost to disease.” Further details on the study methodology and outcomes were not disclosed in this announcement.

Newsflash | Powered by GeneOnline AI

Source: https://www.worldpharmanews.com/bayer/6822-bluerock-therapeutics-announces-publication-in-nature-of-18-month-data-from-phase-1-clinical-trial-for-bemdaneprocel-an-investigational-cell-therapy-for-parkinsons-disease

Author

Mark Chiang